← Back to Clinical Trials
Recruiting NCT04134169
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Trial Parameters
Condition Rheumatoid Arthritis
Sponsor Kang Stem Biotech Co., Ltd.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 28
Sex ALL
Min Age 19 Years
Max Age 80 Years
Start Date 2019-10-02
Completion 2025-08-11
Interventions
Not applicable(observational study)
Brief Summary
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Eligibility Criteria
Inclusion Criteria: 1. Subject who enrolled K0202 Clinical Trial(parent study) and has been given more than one medication. 2. Subjects who understand and voluntarily sign an informed consent form Exclusion Criteria: 1\. Any other condition which the investigator judges would make patient unsuitable for study participation